References

pulmo

Пульмонология

PULMONOLOGIYA

0869-01892541-9617

Scientific and Practical Journal “PULMONOLOGIYA” LLC

10.18093/0869-0189-2009-5-9-63

pulmo-1580

Research Article

Статьи

Интерстициальные заболевания легких: клинические рекомендации Британского торакального общества совместно с Торакальным обществом Австралии и Новой Зеландии и Ирландским торакальным обществом. Часть 2

Веллс

А. У.

noemail@neicon.ru

Хирани

Н. .

noemail@neicon.ru

2009

28102009

05963

2009

Веллс А.У., Хирани Н...

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.pulmonology.ru/pulm/article/view/1580

References1

Cushley M.J., Davison A.G., du Bois R.M. et al. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54: S1-S30.

American Thoracic Society / European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277-304.

Katzenstein A.L., Fiorelli R.F. Nonspecific interstitial pneumonia / fibrosis. Histologic features and clinical significance. Am. J. Surg. Pathol. 1994; 18: 136-147.

Nicholson A.G., Colby T.V., du Bois R.M. et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 2000; 162: 2213-2217.

Flaherty K.R., Thwaite E.L., Kazerooni E.A. et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.

Flaherty K.R., King T.E. Jr., Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904-910.

Latsi P.I., du Bois R.M., Nicholson A.G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-537.

Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.

Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-2242.

Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125-133.

Harbour R., Miller J. A new system for grading recommendations in evidence based guidelines. Br. Med. J. 2001; 323: 334-336.

Guyatt G., Vist G., Falck-Ytter Y. et al. An emerging consensus on grading recommendations? ACP J. Club 2006; 144: A8-A9.

Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157: 199-203.

Cottin V., Donsbeck A.V., Revel D. et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am. J. Respir. Crit. Care Med. 1998; 158: 1286-1293.

Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1999; 160: 899-905.

Nagai S., Kitaichi M., Itoh H. et al. Idiopathic nonspecific interstitial pneumonia / fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur. Respir. J. 1998; 12: 1010-1019.

Schwartz D.A., Van Fossen D.S., Davis C.S. et al. Determinants of progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1994; 149: 444-449.

Travis W.D., Matsui K., Moss J. et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am. J. Surg. Pathol. 2000; 24: 19-33. 19. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.

Wells A.U., Hansell D.M., Nicholson A.G. What is this thing called CFA? Thorax 2007; 62: 3-4.

Nicholson A.G., Addis B.J., Bharucha H. et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500-505.

Hunninghake G.W., Zimmerman M.B., Schwartz D.A. et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 193-196.

Raghu G., Mageto Y.N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest 1999; 116: 1168-1174.

Wells A.U. Histopathologic diagnosis in diffuse lung disease: an ailing gold standard. Am. J. Respir. Crit. Care Med. 2004; 170: 828-829.

Wells A.U., Nicholson A.G., Hansell D.M. Challenges in pulmonary fibrosis 4: Smokinginduced diffuse interstitial lung diseases. Thorax 2007; 62: 904-910.

Vourlekis J.S., Schwarz M.I., Cool C.D. et al. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am. J. Med. 2002; 112: 490-493.

Churg A., Muller N.L., Flint J. et al. Chronic hypersensitivity pneumonitis. Am. J. Surg. Pathol. 2006; 30: 201-208.

Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165: 1581-1586.

Yoshinouchi T., Ohtsuki Y., Fujita J. et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol. Int. 2005; 26: 121-125.

Selman M., Pardo A., Barrera L. et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006; 173: 188-198.

Yang I.V., Burch L.H., Steele M.P. et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2007; 175: 45-54.

MacDonald S.L., Rubens M.B., Hansell D.M. et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221: 600-605.

Kim T.S., Lee K.S., Chung M.P. et al. Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. Am. J. Roentgenol. 1998; 171: 1645-1650.

Park J.S., Lee K.S., Kim J.S. et al. Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in seven patients. Radiology 1995; 195: 645-648.

Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990; 84: 365-369.

Doherty M.J., Pearson M.G., O'Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.

Collard H.R., King T.E. Jr., Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538-542.

Flaherty K.R., Mumford J.A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 543-548.

Jegal Y., Kim D.S., Shim T.S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005;171: 639-644.

King T.E. Jr., Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127: 171-177.

King T.E. Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. 2000; 342: 974-975.

Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.

Hunninghake G.W. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2285-2287.

Wells A.U. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur. Respir. J. 2006; 27: 664-666.

Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136-151.

Lok S.S. Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. Greater Manchester Lung Fibrosis Consortium. J. Heart Lung Transplant. 1999; 18: 884-890.

Hubbard R., Johnston I., Coultas D.B. et al. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51: 711-716.

Coultas D.B., Zumwalt R.E., Black W.C. et al. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967-972.

Thomeer M.J., Costabe U., Rizzato G. et al. Comparison of registries of interstitial lung diseases in three European countries. Eur. Respir. J. Suppl 2001; 32: 114s-118s.

von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir. Med. 2003; 97: 428-435.

Hansell A., Hollowell J., Nichols T. et al. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999; 54: 413-419.

Hubbard R., Johnston I., Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396-400.

Hubbard R., Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002; 41: 676-679.

Johnston I., Britton J., Kinnear W. et al. Rising mortality from cryptogenic fibrosing alveolitis. Br. Med. J. 1990; 301: 1017-1021.

Baumgartner K.B., Samet J.M., Coultas D.B. et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am. J. Epidemiol. 2000; 152: 307-315.

Iwai K., Mori T., Yamada N. et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994; 150: 670-675.

Palwatwichai A., Tiyanon W., Chaoprasong C. et al. Idiopathic pulmonary fibrosis, clinical features in Thai patients. J. Med. Assoc. Thai 2000; 83: 1248-1252.

Smith C., Feldman C., Levy H. et al. Cryptogenic fibrosing alveolitis. A study of an indigenous African population. Respiration 1990; 57: 364-371.

Mapel D.W., Hunt W.C., Utton R. et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998; 53: 469-476.

Hubbard R., Venn A., Lewis S. et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000; 161: 5-8.

Turner-Warwick M., Lebowitz M., Burrows B. et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.

Pietinalho A., Hiraga Y., Hosoda Y. et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995; 12: 61-67.

Rybicki B.A., Major M., Popovich J. Jr. et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am. J. Epidemiol. 1997; 145: 234-241.

Baughman R.P., Teirstein A.S., Judson M.A. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care Med. 2001; 164: 1885-1889.

Byg K.E., Milman N., Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20: 46-52.

Kajdasz D.K., Judson M.A., Mohr L.C. Jr. et al. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am. J. Epidemiol. 1999; 150: 271-278.

Reich J.M. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39.

Gideon N.M., Mannino D.M. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am. J. Med. 1996; 100: 423-427.

Xaubet A., Ancochea J., Morell F. et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidos. Vasc. Diffuse Lung Dis. 2004; 21: 64-70.

Bourke S.J., Dalphin J.C., Boyd G. et al. Hypersensitivity pneumonitis: current concepts. Eur. Respir. J. 2001; 18: 81-92s.

Hendrick D.J., Faux J.A., Marshall R. Budgerigar-fancier's lung: the commonest variety of allergic alveolitis in Britain. Br. Med. J. 1978; 2: 81-84.

Vourlekis J.S., Schwarz M.I., Cherniack R.M. et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am. J. Med. 2004; 116: 662-668.

Tukiainen P., Taskinen E., Holsti P. et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-355.

Dawson J.K., Fewins H.E., Desmond J. et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-627.

Dawson J.K., Fewins H.E., Desmond J. et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2002; 61: 517-521.

Wells A.U., Cullinan P., Hansell D.M. et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1994; 149: 1583-1590.

Donaghy M., Rees A.J. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2: 1390-1393.

Baumgartner K.B., Samet J.M., Stidley C.A. et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997; 155: 242-248.

Kusaka H., Homma Y., Ogasawara H. et al. Five-year follow-up of Micropolyspora faeni antibody in smoking and nonsmoking farmers. Am. Rev. Respir. Dis. 1989; 140: 695-699.

Valeyre D., Soler P., Clerici C. et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 1988; 43: 516-524.

Brennan N.J., Crean P., Long J.P. et al. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984; 39: 14-18.

McGrath D.S., Daniil Z., Foley P. et al. Epidemiology of familial sarcoidosis in the UK. Thorax 2000; 55: 751-754.

Schurmann M., Lympany P.A., Reichel P. et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am. J. Respir. Crit. Care Med. 2000; 162: 861-864.

Barzo P. Familial idiopathic fibrosing alveolitis. Eur. J. Respir. Dis. 1985; 66: 350-352.

Cooper J.A. Jr., White D.A., Matthay R.A. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 488-505.

Cooper J.A. Jr., White D.A., Matthay R.A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 321-340.

Johnston I.D., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52: 38-44.

Kanematsu T., Kitaichi M., Nishimura K. et al. Clubbing of the fingers and smoothmuscle proliferation in fibrotic changes in the lung in patients with idiopathic pulmonary fibrosis. Chest 1994; 105: 339-342.

Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.

Coutts I.I., Gilson J.C., Kerr I.H. et al. Significance of finger clubbing in asbestosis. Thorax 1987; 42: 117-119.

Sansores R., Salas J., Chapela R. et al. Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role. Arch. Intern. Med. 1990; 150: 1849-1851.

Grathwohl K.W., Thompson J.W., Riordan K.K. et al. Digital clubbing associated with polymyositis and interstitial lung disease. Chest 1995; 108: 1751-1752.

Epler G.R., Carrington C.B., Gaensler E.A. Crackles (rales) in the interstitial pulmonary diseases. Chest 1978; 73: 333-339.

Harrison N.K., Glanville A.R., Strickland B. et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir. Med. 1989; 83: 403-414.

Baughman R.P., Shipley R.T., Loudon R.G. et al. Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis. Chest 1991; 100: 96-101.

Earis J.E., Marsh K., Pearson M.G. et al. The inspiratory ''squawk'' in extrinsic allergic alveolitis and other pulmonary fibroses. Thorax 1982; 37: 923-926.

Panos R.J., Mortenson R.L., Niccoli S.A. et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 1990; 88: 396-404.

Sharma O.P., Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988; 94: 343-346.

Harrison B.D., Shaylor J.M., Stokes T.C. et al. Airflow limitation in sarcoidosis-a study of pulmonary function in 107 patients with newly diagnosed disease. Respir. Med. 1991; 85: 59-64.

Crausman R.S., Jennings C.A., Tuder R.M. et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am. J. Respir. Crit. Care Med. 1996; 153: 426-435.

100

Delobbe A., Durieu J., Duhamel A. et al. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur. Respir. J. 1996; 9: 2002-2006.

101

Kitaichi M., Nishimura K., Itoh H. et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med. 1995; 151: 527-533.

102

Taylor J.R., Ryu J., Colby T.V. et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N. Engl. J. Med. 1990; 323: 1254-1260.

103

Hanley M.E, King T.E. Jr., Schwarz M.I. et al. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am. Rev. Respir. Dis. 1991; 144: 1102-1106.

104

Schwartz D.A., Merchant R.K., Helmers R.A. et al. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1991; 144: 504-506.

105

Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962-969.

106

Schwartz D.A., Helmers R.A., Galvin J.R. et al. Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1994; 149: 450-454.

107

Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063-1072.

108

Mogulkoc N., Brutsche M.H., Bishop P.W. et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am. J. Respir. Crit. Care Med. 2001; 164: 103-108.

109

Egan J.J., Martinez F.J., Wells A.U. et al. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60: 270-273.

110

Watters L.C., King T.E., Schwarz M.I. et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1986; 133: 97-103.

111

King T.E. Jr, Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171-1181.

112

Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26: 948-68.

113

Hanson D., Winterbauer R.H., Kirtland S.H. et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305-310.

114

Neville E., Walker A.N., James D.G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Quart. J. Med. 1983; 52: 525-533.

115

Sharma O.P. Pulmonary sarcoidosis and corticosteroids. Am. Rev. Respir. Dis. 1993; 147: 1598-1600.

116

Lynch J.P. III, Kazerooni E.A., Gay S.E. Pulmonary sarcoidosis. Clin. Chest Med. 1997; 18: 755-785.

117

Gibson G.J., Prescott R.J., Muers M.F. et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.

118

Lin Y.H., Haslam P.L., Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40: 501-507.

119

Muller N.L., Mawson J.B., Mathieson J.R. et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989; 171: 613-618.

120

Muers M.F., Middleton W.G., Gibson G.J. et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidos. Vasc. Diffuse Lung Dis. 1997; 14: 46-56.

121

Hansell D.M., Milne D.G., Wilsher M.L. et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998; 209: 697-704.

122

Drent M., De V.J., Lenters M. et al. Sarcoidosis: assessment of disease severity using HRCT. Eur. Radiol. 2003; 13: 2462-2471.

123

Alhamad E.H., Lynch J.P. III, Martinez F.J. Pulmonary function tests in interstitial lung disease: what role do they have? Clin. Chest Med. 2001; 22: 715-750, ix.

124

Lieberman J., Schleissner L.A., Nosal A. et al. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983; 84: 522-528.

125

Shorr A.F., Davies D.B., Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-928.

126

Goldstein D.S., Williams M.H. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax 1986; 41: 473-474.

127

Johns C.J., Schonfeld S.A., Scott P.P. et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann. N. Y. Acad. Sci. 1986; 465: 702-712.

128

Odlum C.M., Fitzgerald M.X. Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis. Sarcoidosis 1986; 3: 40-46.

129

Judson M.A., Baughman R.P., Thompson B.W. et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidos. Vasc. Diffuse Lung Dis. 2003; 20: 204-211.

130

Keogh B.A., Crystal RG. Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 1980; 78: 856-865.

131

Keogh B.A., Lakatos E., Price D. et al. Importance of the lower respiratory tract in oxygen transfer. Exercise testing in patients with interstitial and destructive lung disease. Am. Rev. Respir. Dis. 1984; 129: S76-S80.

132

Miller A., Brown L.K., Sloane M.F. et al. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995; 107: 323-329.

133

Marciniuk D.D., Gallagher C.G. Clinical exercise testing in interstitial lung disease. Clin. Chest Med. 1994; 15: 287-303.

134

Fulmer J.D., Roberts W.C., von Gal E.R. et al. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J. Clin. Invest. 1979; 63: 665-676.

135

Wells A.U., King A.D., Rubens M.B. et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am. J. Respir. Crit. Care Med. 1997; 155: 1367-1375.

136

Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthr. and Rheum. 1997; 40: 1229-1236.

137

Agusti C., Xaubet A., Agusti A.G. et al. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur. Respir. J. 1994; 7: 643-50.

138

Risk C., Epler G.R., Gaensler E.A. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984; 85: 69-74.

139

Flaherty K.R., Andrei A.C., Murray S. et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 2006; 174: 803-809.

140

Hallstrand T.S., Boitano L.J., Johnson W.C. et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. 2005; 25: 96-103.

141

Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 1084-1090.

142

Lettieri C.J., Nathan S.D., Browning RF. et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir. Med. 2006; 100: 1734-1741.

143

Eaton T., Young P., Milne D. et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 1150-1157.

144

Kawut S.M., O'Shea M.K., Bartels M.N. et al. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir. Med. 2005; 99: 1431-1439.

145

Moloney E.D., Clayton N., Mukherjee D.K. et al. The shuttle walk exercise test in idiopathic pulmonary fibrosis. Respir. Med. 2003; 97: 682-687.

146

Epler G.R., McLoud T.C., Gaensler E.A. et al. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N. Engl. J. Med. 1978; 298: 934-939.

147

Gaensler E.A., Carrington C.B. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann. Thorac. Surg. 1980; 30: 411-426.

148

Mathieson J.R., Mayo J.R., Staples C.A. et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989; 171: 111-116.

149

McLoud T.C., Carrington C.B., Gaensler E.A. Diffuse infiltrative lung disease: a new scheme for description. Radiology 1983; 149: 353-363.

150

Schaefer-Prokop C., Uffmann M., Eisenhuber E. et al. Digital radiography of the chest: detector techniques and performance parameters. J. Thorac. Imag. 2003; 18: 124-137.

151

Mayo J.R., Webb W.R., Gould R. et al. High-resolution CT of the lungs: an optimal approach. Radiology 1987; 163: 507-510.

152

Johkoh T., Muller N.L., Nakamura H. Multidetector spiral high-resolution computed tomography of the lungs: distribution of findings on coronal image reconstructions.J. Thorac. Imag. 2002; 17: 291-305.

153

Remy-Jardin M., Campistron P., Amara A. et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J. Comput. Assist. Tomogr. 2003; 27: 266-273.

154

Mayo J.R., Aldrich J., Muller N.L. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 2003; 228: 15-21.

155

Muller N.L., Kullnig P., Miller R.R. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. Am. J. Roentgenol. 1989; 152: 1179-1182.

156

Padley S.P., Adler B., Muller N.L. High-resolution computed tomography of the chest: current indications. J. Thorac. Imag. 1993; 8: 189-199.

157

Padley S.P., Hansell D.M., Flower CD. et al. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin. Radiol. 1991; 44: 222-226.

158

Lynch D.A., Rose C.S., Way D. et al. Hypersensitivity pneumonitis: sensitivity of highresolution CT in a population-based study. A.J.R. Am. J. Roentgenol. 1992; 159: 469-472.

159

Orens J.B., Kazerooni E.A., Martinez F.J. et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest 1995; 108: 109-115.

160

Dalal P.U., Hansell D.M. High-resolution computed tomography of the lungs: the borderlands of normality. Eur. Radiol. 2006; 16: 771-780.

161

Remy-Jardin M., Remy J., Boulenguez C. et al. Morphologic effects of cigarette smoking on airways and pulmonary parenchyma in healthy adult volunteers: CT evaluation and correlation with pulmonary function tests. Radiology 1993; 186: 107-115.

162

Remy-Jardin M., Edme J.L., Boulenguez C. et al. Longitudinal follow-up study of smoker's lung with thin-section CT in correlation with pulmonary function tests. Radiology 2002; 222: 261-270.

163

Grenier P., Chevret S., Beigelman C. et al. Chronic diffuse infiltrative lung disease: determination of the diagnostic value of clinical data, chest radiography, and CT and Bayesian analysis. Radiology 1994; 191: 383-390.

164

Hartman T.E., Swensen S.J., Hansell D.M. et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology 2000; 217: 701-705.

165

Aziz Z.A., Wells A.U., Hansell D.M. et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59: 506-511.

166

Wells A.U., Rubens M.B., du Bois R.M. et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am. J. Roentgenol. 1993; 161: 1159-1165.

167

Remy-Jardin M., Giraud F., Remy J. et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693-698.

168

Sheehan R.E., Wells A.U., Milne D.G. et al. Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. J. Comput. Assist. Tomogr. 2000; 24: 259-261.

169

Muller N.L., Miller R.R., Webb W.R. et al. Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986; 160: 585-588.

170

Dawson J.K., Fewins H.E., Desmond J. et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2002; 61: 517-521.

171

Harrison B.J. Influence of cigarette smoking on disease outcome in rheumatoid arthritis. Curr. Opin. Rheumatol. 2002; 14: 93-97.

172

Klareskog L., Stolt P., Lundberg K. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthr. and Rheum. 2006; 54: 38-46.

173

McDonagh J., Greaves M., Wright A.R. et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 1994; 33: 118-122.

174

Saag K.G., Kolluri S., Koehnke R.K. et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthr. and Rheum. 1996; 39: 1711-1719.

175

Stolt P., Bengtsson C., Nordmark B. et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 2003; 62: 835-841.

176

Hesselstrand R., Scheja A., Shen G.Q. et al. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-540.

177

Douglas W.W., Tazelaar H.D., Hartman T.E. et al. Polymyositis-dermatomyositisassociated interstitial lung disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1182-1185.

178

Costabel U., Hunninghake G.W. ATS / ERS / WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 1999; 14: 735-737.

179

Gupta D., Chetty M., Kumar N. et al. Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidos. Vasc. Diffuse Lung Dis. 2003; 20: 40-45.

180

Morell F., Levy G., Orriols R. et al. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest 2002; 121: 1239-1244.

181

Newman L.S., Rose C.S., Maier L.A. Sarcoidosis. N. Engl. J. Med. 1997; 336: 1224-1234.

182

Leung A.N., Brauner M.W., Caillat-Vigneron N. et al. Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay. J. Comput. Assist. Tomogr. 1998; 22: 229-234.

183

Shorr A.F., Torrington K.G., Parker J.M. Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis. Respir. Med. 1997; 91: 399-401.

184

Takada K., Ina Y., Noda M. et al. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J. Clin. Epidemiol. 1993; 46: 359-366.

185

Marshall B.G., Shaw R.J. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax 1998; 53: 439-440.

186

Stokes G.S., Monaghan J.C., Schrader A.P. et al. Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity. Aust. N. Z. J. Med. 1999; 29: 315-318.

187

Tahmoush A.J., Amir M.S., Connor W.W. et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidos. Vasc. Diffuse Lung Dis. 2002; 19: 191-197.

188

Sharma O.P. Hypercalcemia in granulomatous disorders: a clinical review. Curr. Opin. Pulm. Med. 2000; 6: 442-447.

189

Larsen F., Pehrsson S.K., Hammar N. et al. ECG-abnormalities in Japanese and Swedish patients with sarcoidosis. A comparison. Sarcoidos. Vasc. Diffuse Lung Dis. 2001; 18: 284-288.

190

Burrell R., Rylander R. A critical review of the role of precipitins in hypersensitivity pneumonitis. Eur. J. Respir. Dis. 1981; 62: 332-343.

191

Marcer G., Simioni L., Saia B. et al. Study of immunological parameters in farmer's lung. Clin. Allergy 1983; 13: 443-449.

192

Husman K., Vohlonen I., Terho E.O. et al. Precipitins against microbes in mouldy hay in the sera of farmers with farmer's lung or chronic bronchitis and of healthy farmers. Eur. J. Respir. Dis. Suppl. 1987; 152: 122-127.

193

Fink J.N., Ortega H.G., Reynolds H.Y. et al. Needs and opportunities for research in hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2005; 171: 792-798.

194

Ohtani Y., Kojima K., Sumi Y. et al. Inhalation provocation tests in chronic bird fancier's lung. Chest 2000; 118: 1382-1389.

195

Ramirez-Venegas A., Sansores R.H., Perez-Padilla R. et al. Utility of a provocation test for diagnosis of chronic pigeon Breeder's disease. Am. J. Respir. Crit. Care Med. 1998; 158: 862-869.

196

Yoshida K., Ando M., Sakata T. et al. Environmental mycological studies on the causative agent of summer-type hypersensitivity pneumonitis. J. Allergy Clin. Immunol. 1988; 81: 475-483. 198. British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56 (suppl. 1): i1-i21.

197

Credle W.F. Jr., Smiddy J.F., Elliott R.C. Complications of fiberoptic bronchoscopy. Am. Rev. Respir. Dis. 1974; 109: 67-72.

198

Pue C.A., Pacht E.R. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995; 107: 430-432.

199

Zavala D.C. Diagnostic fiberoptic bronchoscopy: techniques and results of biopsy in 600 patients. Chest 1975; 68: 12-19.

200

Herf S.M., Suratt P.M., Arora N.S. Deaths and complications associated with transbronchial lung biopsy. Am. Rev. Respir. Dis. 1977; 115: 708-711.

201

Andersen H.A. Transbronchoscopic lung biopsy for diffuse pulmonary diseases. Results in 939 patients. Chest 1978; 73: 734-736.

202

Simpson F.G., Arnold A.G., Purvis A. et al. Postal survey of bronchoscopic practice by physicians in the United Kingdom. Thorax 1986; 41: 311-317.

203

Descombes E., Gardiol D., Leuenberger P. Transbronchial lung biopsy: an analysis of 530 cases with reference to the number of samples. Monaldi Arch. Chest Dis. 1997; 52: 324-329.

204

Mitchell D.M., Emerson C.J., Collins J.V. et al. Transbronchial lung biopsy with the fibreoptic bronchoscope: analysis of results in 433 patients. Br. J. Dis. Chest 1981; 75: 258-262.

205

Zavala D.C. Pulmonary hemorrhage in fiberoptic transbronchial biopsy. Chest 1976; 70: 584-588.

206

Papin T.A., Lynch III J.P., Weg J.G. Transbronchial biopsy in the thrombocytopenic patient. Chest 1985; 88: 549-552.

207

Herth F.J., Becker H.D., Ernst A. Aspirin does not increase bleeding complications after transbronchial biopsy. Chest 202; 122: 1461-1464.

208

Haponik E.F., Summer W.R., Terry P.B. et al. Clinical decision making with transbronchial lung biopsies. The value of nonspecific histologic examination. Am. Rev. Respir. Dis. 1982; 125: 524-529.

209

Haslam P.L., Baughman R.P. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur. Respir. J. 1999; 14: 245-248. 212. Anon. Technical recommendations and guidelines for bronchoalveolar lavage (VBAL). Report of the European Society of Pneumology Task Group. Eur. Respir. J. 1989; 2: 561-285. 213. Anon. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. The BAL Cooperative Group Steering Committee. Am. Rev. Respir. Dis. 1990; 141: S169-S202.

210

Garcia J.G., Wolven R.G., Garcia P.L. et al. Assessment of interlobar variation of bronchoalveolar lavage cellular differentials in interstitial lung diseases. Am. Rev. Respir. Dis. 1986; 133: 444-449.

211

Peterson M.W., Nugent K.M., Jolles H. et al. Uniformity of bronchoalveolar lavage in patients with pulmonary sarcoidosis. Am. Rev. Respir. Dis. 1988; 137: 79-84.

212

Frigieri L., Mormile F., Grillie N. et al. Bilateral bronchoalveolar lavage in progressive systemic sclerosis: interlobar variability, lymphocyte subpopulations and functional correlations. Respiration 1991; 58: 132-140.

213

Agusti C., Xaubet A., Luburich P. et al. Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis. Thorax 1996; 51: 841-845.

214

Baughman R.P. Use of bronchoscopy in the diagnosis of infection in the immunocompromised host. Thorax 1994; 49: 3-7.

215

Betsuyaku T., Munakata M., Yamaguchi E. et al. Establishing diagnosis of pulmonary malignant lymphoma by gene rearrangement analysis of lymphocytes in bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med. 1994; 149: 526-529.

216

Martin R.J., Coalson J.J., Rogers R.M. et al. Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am. Rev. Respir. Dis. 1980; 121: 819-825.

217

Winterbauer R.H., Lammert J., Selland M. et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104: 352-361.

218

Kantrow S.P., Meyer K.C., Kidd P. et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur. Respir. J. 1997; 10: 2716-2721.

219

Costabel U., Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr. Opin. Pulm. Med. 2001; 7: 255-261.

220

Drent M., van Nierop M.A., Gerritsen F.A. et al. A computer program using BALF analysis results as a diagnostic tool in interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1996; 153: 736-741.

221

Drent M., Grutters J.C., Mulder P.G. et al. Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Sarcoidos. Vasc. Diffuse Lung Dis. 1997; 14: 31-38.

222

Drent M., Jacobs J.A., De V.J. et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur. Respir. J. 1999; 13: 1338-1344.

223

Ziegenhagen M.W., Rothe M.E., Schlaak M. et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur. Respir. J. 2003; 21: 407-413.

224

Park C.S., Chung S.W., Ki S.Y. et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic non-specific interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2000; 162: 1162-1168.

225

Veeraraghavan S., Latsi P.I., Wells AU. et al. BAL findings in idiopathic non-specific interstitial pneumonia and usual interstitial pneumonia. Eur. Respir. J. 2003; 22: 239-244.

226

Drent M., du Bois R.M., Poletti V. Recent advances in the diagnosis and management of nonspecific interstitial pneumonia. Curr. Opin. Pulm. Med. 2003; 9: 411-417.

227

Gabbay E., Tarala R., Will R. et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 1997; 156: 528-535.

228

Wallaert B., Hatron P.Y., Grosbois J.M. et al. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am. Rev. Respir. Dis. 1986; 133: 574-580.

229

Silver R.M., Miller K.S., Kinsella M.B. et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 1990; 88: 470-476.

230

White B., Moore W.C., Wigley F.M. et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 2000; 132: 947-954.

231

Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am. J. Respir. Crit. Care Med. 1994; 150: 462-468.

232

Wells A.U., Hansell D.M., Haslam P.L. et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am. J. Respir. Crit. Care Med. 1998; 157: 1474-1482.

233

Fechner R.E. Greenberg S.D, Wilson R.K. et al. Evaluation of transbronchial biopsy of the lung. Am. J. Clin. Pathol. 1977; 68: 17-20.

234

Wall C.P., Gaensler E.A., Carrington C.B. et al. Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am. Rev. Respir. Dis. 1981; 123: 280-285.

235

Poletti V., Patelli M., Ferracini R. et al. Transbronchial lung biopsy in infiltrative lung disease. The importance of the pathologic approach. Sarcoidosis 1988; 5: 43-50.

236

Mitchell D.M., Mitchell D.N., Collins J.V. et al. Transbronchial lung biopsy through fibreoptic bronchoscope in diagnosis of sarcoidosis. Br. Med. J. 1980; 280: 679-681.

237

Puar H.S., Young Jr. R.C., Armstrong E.M. Bronchial and transbronchial lung biopsy without fluoroscopy in sarcoidosis. Chest 1985; 87: 303-306.

238

Glaspole I.N., Wells A.U., du Bois R.M. Lung biopsy in diffuse parenchymal lung disease. Monaldi Arch. Chest Dis. 2001; 56: 225-232.

239

Gilman M.J., Wang K.P. Transbronchial lung biopsy in sarcoidosis. An approach to determine the optimal number of biopsies. Am. Rev. Respir. Dis. 1980; 122: 721-724.

240

Curley F.J., Johal J.S., Burke M.E. et al. Transbronchial lung biopsy: can specimen quality be predicted at the time of biopsy? Chest 1998; 113: 1037-1041.

241

Bjermer L., Thunell M., Rosenhall L. et al. Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir. Med. 1991; 85: 229-234.

242

Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001; 120: 109-114.

243

Armstrong J.R., Radke J.R., Kvale P.A. et al. Endoscopic findings in sarcoidosis. Characteristics and correlations with radiographic staging and bronchial mucosal biopsy yield. Ann. Otol. St. Louis. 1981; 90: 339-343.

244

Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001; 120: 881-886.

245

Neuhaus S.J., Matar K.S. The efficacy of open lung biopsy. Aust. N. Z. J. Surg. 1997; 67: 181-184.

246

Qureshi R.A., Soorae A.A. Efficacy of thoracoscopic lung biopsy in interstitial lung diseases: comparison with open lung biopsy. J. Coll. Physicians Surg. Pak. 2003; 13: 600-603.

247

Ray J.F. III, Lawton B.R., Myers WO. et al. Open pulmonary biopsy. Nineteen-year experience with 416 consecutive operations. Chest 1976; 69: 43-47.

248

Shah S.S., Tsang V., Goldstraw P. Open lung biopsy: a safe, reliable and accurate method for diagnosis in diffuse lung disease. Respiration 1992; 59: 243-246.

249

Daniil Z., Gilchrist F.C., Marciniak S.J. et al. The effect of lung biopsy on lung function in diffuse lung disease. Eur. Respir. J. 2000; 16: 67-73.

250

Utz J.P., Ryu J.H., Douglas W.W. et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur. Respir. J. 2001; 17: 175-179.

251

Carrillo G., Estrada A., Pedroza J. et al. Preoperative risk factors associated with mortality in lung biopsy patients with interstitial lung disease. J. Invest. Surg. 2005; 18: 39-45.

252

Lettieri C.J., Veerappan G.R., Helman D.L. et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127: 1600-1605.

253

Kramer M.R., Berkman N., Mintz B. et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann. Thorac. Surg. 1998; 65: 198-202.

254

Qureshi R.A., Ahmed T.A., Grayson A.D. et al. Does lung biopsy help patients with interstitial lung disease? Eur. J. Cardiothorac. Surg. 2002; 21: 621-626.

255

Sedrakyan A., van der M.J., Lewsey J. et al. Variation in use of video assisted thoracic surgery in the United Kingdom. Br. Med. J. 2004; 329: 1011-1012.

256

Ayed A.K., Raghunathan R. Thoracoscopy versus open lung biopsy in the diagnosis of interstitial lung disease: a randomised controlled trial. J. Roy. Coll. Surg. Edinb. 2000; 45: 159-163.

257

Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647-1650.

258

Santambrogio L., Nosotti M., Bellaviti N. et al. Videothoracoscopy versus thoracotomy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann. Thorac. Surg. 1995; 59: 868-870.

259

Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax 1994; 49: 361-363.

260

Hazelrigg S.R., Nunchuck S.K., Landreneau R.J. et al. Cost analysis for thoracoscopy: thoracoscopic wedge resection. Ann. Thorac. Surg. 1993; 56: 633-635.

261

Molin L.J., Steinberg J.B., Lanza L.A. VATS increases costs in patients undergoing lung biopsy for interstitial lung disease. Ann. Thorac. Surg. 1994; 58: 1595-1698.

262

Sugi K., Kaneda Y., Nawata K. et al. Cost analysis for thoracoscopy: thoracoscopic wedge resection and lobectomy. Surg. Today 1998; 28: 41-45.

263

Kramer M.R., Berkman N., Mintz B. et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann. Thorac. Surg. 1998; 65: 198-202.

264

Newman S.L., Michel R.P., Wang N.S. Lingular lung biopsy: is it representative? Am. Rev. Respir. Dis. 1985;132: 1084-1086.

265

Chechani V., Landreneau R.J., Shaikh S.S. Open lung biopsy for diffuse infiltrative lung disease. Ann. Thorac. Surg. 1992; 54: 296-300.

266

Miller R.R., Nelems B., Muller N.L. et al. Lingular and right middle lobe biopsy in the assessment of diffuse lung disease. Ann. Thorac. Surg. 1987; 44: 269-273.

267

Temes R.T., Joste N.E., Allen N.L. et al. The lingula is an appropriate site for lung biopsy. Ann. Thorac. Surg. 2000; 69: 1016-1018.

268

Wetstein L. Sensitivity and specificity of lingular segmental biopsies of the lung. Chest 1986; 90: 383-386.

269

Katzenstein A.L., Zisman D.A., Litzky L.A. et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am. J. Surg. Pathol. 2002; 26: 1567-1577.

270

Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722-1727.

271

Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125: 522-526.

272

Yung R.C., Weinacker A.B., Steiger D.J. et al. Upper and middle lobe bronchoalveolar lavage to diagnose Pneumocystis carinii pneumonia. Am. Rev. Respir. Dis. 1993; 148: 1563-1566.

273

Taylor I.K., Coker R.J., Clarke J. et al. Pulmonary complications of HIV disease: 10 year retrospective evaluation of yields from bronchoalveolar lavage, 1983-1993. Thorax 1995; 50: 1240-1245.

274

Unger E.R., Budgeon L.R., Myerson D. et al. Viral diagnosis by in situ hybridization. Description of a rapid simplified colorimetric method. Am. J. Surg. Pathol. 1986; 10: 1-8.

275

Turner-Warwick M., Lebowitz M., Burrows B. et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.

276

West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999.

277

Arima K., Ando M., Ito K. et al. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch. Environ/ Hlth 1992; 47: 274-278.

278

Baldwin C.I., Todd A., Bourke S. et al. Pigeon fanciers' lung: effects of smoking on serum and salivary antibody responses to pigeon antigens. Clin. Exp. Immunol. 1998; 113: 166-172.

279

Dalphin J.C., Debieuvre D., Pernet D. et al. Prevalence and risk factors for chronic bronchitis and farmer's lung in French dairy farmers. Br. J. Industr. Med. 1993; 50: 941-944.

280

Depierre A., Dalphin J.C., Pernet D. et al. Epidemiological study of farmer's lung in five districts of the French Doubs province. Thorax 1988; 43: 429-435.

281

Douglas J.G., Middleton W.G., Gaddie J. et al. Sarcoidosis: a disorder commoner in non-smokers? Thorax 1986; 41: 787-791.

282

Harf R.A., Ethevenaux C., Gleize J. et al. Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. Ann. N. Y. Acad. Sci. 1986; 465: 625-631.

283

McSharry C., Banham S.W., Boyd G. Effect of cigarette smoking on the antibody response to inhaled antigens and the prevalence of extrinsic allergic alveolitis among pigeon breeders. Clin. Allergy 1985; 15: 487-494.

284

Ohtsuka Y., Munakata M., Tanimura K. et al. Smoking promotes insidious and chronic farmer's lung disease, and deteriorates the clinical outcome. Intern. Med. 1995; 34: 966-971.

285

Jastrzebski D., Gumola A., Gawlik R. et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57 (suppl. 4): 139-148.

286

Naji N.A., Connor M.C., Donnelly S.C. et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237-243.

287

Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary Rehabilitation: Joint ACCP / AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S-42S.

288

De Vries J., Kessels B.L., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2001; 17: 954-961.

289

Crockett A.J., Cranston J.M., Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst. Rev. 2001: CD002883.

290

Clark M., Cooper B., Singh S. et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482-486.

291

Polosa R., Simidchiev A., Walters E.H. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst. Rev. 2002: CD002872.

292

Doherty M.J., Mister R., Pearson M.G. et al. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000; 55: 1028-1032.

293

Hope-Gill B.D., Hilldrup S., Davies C. et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 995-1002.

294

Hansen-Flaschen J. Advanced lung disease. Palliation and terminal care. Clin. Chest Med. 1997; 18: 645-655.

295

Tobin R.W., Pope C.E., Pellegrini C.A. et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1804-1808.

296

Raghu G., Freudenberger T.D., Yang S. et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 27: 136-142.

297

Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794-800.

298

Franquet T., Gimenez A., Torrubia S. et al. Spontaneous pneumothorax and pneumomediastinum in IPF. Eur. Radiol. 2000; 10: 108-113.

299

Kumar P., Goldstraw P., Yamada K. et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J. Thorac. Cardiovasc. Surg. 2003; 125: 1321-1327.

300

Raghu G., Nyberg F., Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 2004; 91 (suppl. 2): S3-S10.

301

Carrington C.B., Gaensler E.A., Coutu R.E. et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 1978; 298: 801-809.

302

Scadding J.G. Chronic diffuse interstitial fibrosis of the lungs. Br. Med. J. 1960; 1: 443-450.

303

Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996; 110: 1058-1067.

304

Millar A. Anti-cytokine therapy in fibrosing alveolitis: where are we now? Respir. Res. 2000; 1: 3-5.

305

Nagai S., Kitaichi M., Hamada K. et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidos. Vasc. Diffuse Lung Dis. 1999; 16: 209-214.

306

Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000;161: 1172-1178.

307

Magro C.M., Allen J., Pope-Harman A. et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol. 2003; 119: 556-567.

308

Lynch J.P. III, White E., Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2001; 7: 298-308.

309

Richeldi L., Davies H.R., Ferrara G. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003: CD002880.

310

Winterbauer R.H., Hammar S.P., Hallman K.O. et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone / azathioprine. Am. J. Med. 1978; 65: 661-672.

311

Raghu G., DePaso W.J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991; 144: 291-296.

312

Cantin A.M., Hubbard R.C., Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1989; 139: 370-372.

313

Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156: 1897-1901.

314

Clark J.G., Dedon T.F., Wayner E.A. et al. Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J. Clin. Invest. 1989; 83: 1505-1511.

315

Narayanan A.S., Whithey J., Souza A. et al. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101: 1326-1331.

316

Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-beta / SMAD signalling by the interferon-gamma / STAT pathway. Nature 1999; 397: 710-713.

317

Okada T., Sugie I., Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res. 1993;12: 87-91.

318

Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999; 341: 1264-1269.

319

Kalra S., Utz J.P., Ryu J.H. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin. Proc. 2003; 78: 1082-1087.

320

Antoniou K.M., Nicholson A.G., Dimadi M. et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 28: 496-504.

321

322

Bajwa E.K., Ayas N.T., Schulzer M. et al. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005; 128: 203-206.

323

Honore I., Nunes H., Groussard O. et al. Acute respiratory failure after interferongamma therapy of end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 953-957.

324

Johnson M.A., Kwan S., Snell N.J. et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.

325

Zisman D.A., Lynch J.P. III, Toews G.B. et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117: 1619-1626.

326

Collard H.R., Ryu J.H., Douglas W.W. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.

327

Baughman R.P., Lower E.E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-1094.

328

Dayton C.S., Schwartz D.A., Helmers R.A. et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993; 103: 69-73.

329

Kolb M., Kirschner J., Riedel W. et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur. Respir. J. 1998; 12: 1409-1414.

330

Lynch J.P. III, McCune W.J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am. J. Respir. Crit. Care Med. 1997; 155: 395-420.

331

Iyer S.N., Gurujeyalakshmi G., Giri S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999; 291: 367-373.

332

Iyer S.N., Wild J.S., Schiedt M.J. et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 1995; 125: 779-785.

333

Gahl W.A., Brantly M., Troendle J. et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 2002; 76: 234-242.

334

Raghu G., Johnson W.C., Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061-1069.

335

Nagai S., Hamada K., Shigematsu M. et al. Open-label compassionate use one year treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 2002; 41: 1118-1123.

336

Carpagnano G.E., Kharitonov S.A., Wells A.U. et al. Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration 2003; 70: 154-160.

337

Giaid A., Michel R.P., Stewart D.J. et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554.

338

Hocher B., Schwarz A., Fagan K.A. et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 2000; 23: 19-26.

339

Mutsaers S.E., Marshall R.P., Goldsack N.R. et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. 1998; 11: 221-225.

340

Park S.H., Saleh D., Giaid A. et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 1997; 156: 600-608.

341

Shahar I., Fireman E., Topilsky M. et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999; 21: 759-775.

342

Miyazaki Y., Araki K., Vesin C. et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995; 96: 250-259.

343

Piguet P.F., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. 1994; 7: 515-518.

344

Thrall R.S., Vogel S.N., Evans R. et al. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 1997; 151: 1303-1310.

345

Freeburn R.W., Armstrong L., Millar A.B. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) inductions. Eur Cytokine Netw 2005; 16: 5-16.

346

Zhang Y., Lee T.C., Guillemin B. et al. Enhanced IL-1 beta and tumor necrosis factor alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 1993; 150: 4188-4196.

347

Chambers R.C. Role of coagulation cascade proteases in lung repair and fibrosis. Eur. Respir. J. Suppl. 2003; 44: 33s-35s.

348

Hernandez-Rodriguez N.A., Cambrey A.D., Harrison N.K. et al. Role of thrombin in pulmonary fibrosis. Lancet 1995; 346: 1071-1073.

349

Imokawa S., Sato A., Hayakawa H. et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 1997; 156: 631-636.

350

Addrizzo-Harris D.J., Harkin T.J., Tchou-Wong K.M. et al. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. Lung 2002; 180: 61-72.

351

Entzian P., Schlaak M., Seitzer U. et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51.

352

Rennard S.I., Bitterman P.B., Ozaki T. et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach to the fibrotic disorders. Am. Rev. Respir. Dis. 1988; 137: 181-185.

353

Douglas W.W., Ryu J.H., Swensen S.J. et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am. J. Respir. Crit. Care Med. 1998; 158: 220-225.

354

Selman M., Carrillo G., Salas J. et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-512.

355

Fedullo A.J., Karlinsky J.B., Snider G.L. et al. Lung statics and connective tissues after penicillamine in bleomycin-treated hamsters. J. Appl. Physiol. 1980; 49: 1083-1090.

356

Geismar L.S., Hennessey S., Reiser K.M. et al. D-penicillamine prevents collagen accumulation in lungs of rats given bleomycin. Chest 1986; 89: 153S-154S.

357

Meier-Sydow J., Rust M., Kronenberger H. et al. [Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or d-penicillamine]. Prax. Klin. Pneumol. 1979; 33 (suppl. 1): 680-688.

358

Borel J.F. Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo. Pharmacol. Rev. 1990; 41: 259-371.

359

Eickelberg O., Pansky A., Koehler E. et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J. 2001; 15: 797-806.

360

Alton E.W., Johnson M., Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir. Med. 1989; 83: 277-279.

The authors declare that there are no conflicts of interest present.